EZH2 and cancer: Mechanistic studies showed that DZNep effectively depletes cellular levels of PRC2 components EZH2, SUZ12 and EED and inhibits histone H3K27 methylation suggesting a unique feature of DZNep as a novel chromatin remodeling compound that could be used as a novel cancer therapeutic [110].